{"version":"1.0","provider_name":"ZoBio - Drug Discovery Technology","provider_url":"https:\/\/zobio.com\/online","author_name":"Content manager ~KB","author_url":"https:\/\/zobio.com\/online\/author\/kasia\/","title":"YTHDF2 \u2013 An unprecedented epitranscriptomic reader protein - ZoBio - Drug Discovery Technology","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"OHe8jI9Nxk\"><a href=\"https:\/\/zobio.com\/online\/cases\/ythdf2-an-unprecedented-epitranscriptomic-reader-protein\/\">YTHDF2 \u2013 An unprecedented epitranscriptomic reader protein<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/zobio.com\/online\/cases\/ythdf2-an-unprecedented-epitranscriptomic-reader-protein\/embed\/#?secret=OHe8jI9Nxk\" width=\"600\" height=\"338\" title=\"&#8220;YTHDF2 \u2013 An unprecedented epitranscriptomic reader protein&#8221; &#8212; ZoBio - Drug Discovery Technology\" data-secret=\"OHe8jI9Nxk\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/zobio.com\/online\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/zobio.com\/online\/wp-content\/uploads\/2020\/01\/JV7A9921-1-e1678356118107.jpg","thumbnail_width":2000,"thumbnail_height":1100,"description":"Challenge Our client tasked us with setting up a complete \u201cgene to lead\u201d fragment-based drug discovery campaign.  Since the entire family is unprecedented, there were no \u201ctool compounds\u201d typically required to set up assays. As we progressed, further challenges presented themselves.   Achievements By capitalizing on our unique expertise in developing customized biophysical assays, we created a biologically relevant compound screening cascade in the absence of tool compounds. The cascade delivered chemically diverse sets of validated fragments that we successfully elaborated towards lead compounds using structural information that could only be gleaned through NMR."}